Comparison of efficacy and safety among axitinib, sunitinib, and sorafenib as neoadjuvant therapy for renal cell carcinoma: a retrospective study

Detalles Bibliográficos
Autores principales: Cai, Wen, Cai, Biao, Zhou, Juan, Chen, Yonghui, Zhang, Jin, Huang, Yiran, Xue, Wei, Huang, Jiwei
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BioMed Central 2019
Materias:
Letter to the Editor
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6788019/
https://www.ncbi.nlm.nih.gov/pubmed/31601263
http://dx.doi.org/10.1186/s40880-019-0405-5

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6788019/
https://www.ncbi.nlm.nih.gov/pubmed/31601263
http://dx.doi.org/10.1186/s40880-019-0405-5

Ejemplares similares